December 16, 2025 — Leads & Copy — KORU Medical Systems, Inc. (NASDAQ: KRMD) announced the appointment of Eric Schiller as Chief Technology Officer, effective December 29, 2025.
Schiller brings over 25 years of leadership experience in research and development, device engineering, drug-device combination product development, supply chain strategy, and product lifecycle management.
In his new role, Schiller will lead KORU’s product development and innovation pipeline, shaping the company’s technology and platform strategy. His experience will be used to integrate portfolio planning with the needs of KORU’s global customer base.
Most recently, Schiller was Global Head of Device Development Portfolio at Sanofi, where he led a global team, advanced delivery platforms, drove regulatory initiatives, and oversaw more than 80 pipeline assets.
Before Sanofi, Schiller spent over a decade at Bristol-Myers Squibb and Celgene in device development, biologics commercialization, and product strategy roles. He supported launches for immunology and hematology assets and implemented programs that improved reliability, patient adherence, and supply continuity. His career also includes roles at Becton Dickinson and Saint-Gobain, where he developed syringe platforms and implemented safety and process-improvement initiatives.
Schiller holds an MBA from Seton Hall University and a Bachelor of Science in Mechanical Engineering from the New Jersey Institute of Technology. He holds more than a dozen U.S. patents in injection devices, safety systems, and drug-delivery components.
Linda Tharby, CEO of KORU Medical Systems, said that Schiller’s expertise in technology leadership will align product innovation with market needs. She added that his experience in devices, engineering, and chemistry manufacturing will be invaluable.
Schiller said KORU is at an exciting point in its growth, with a mission to enhance patient quality of life through subcutaneous drug delivery. He said he is energized to partner with the team to advance platforms, accelerate R&D capabilities, and drive a technology strategy for patients, providers, and pharmaceutical partners.
KORU Medical Systems develops, manufactures, and commercializes large volume subcutaneous infusion solutions. The Freedom System includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System is used for self-administration and/or delivery in an ambulatory infusion center. KORU Medical provides products for use by biopharmaceutical companies in clinical trials and is capable of customizing the Freedom System for clinical and commercial use.
Contact:
[Not specified in press release]
Source: KORU Medical Systems
